MicroPort® EP’s Disposable Intracardiac Mapping Catheter Receives NMPA Approval

Shanghai MicroPort EP MedTech Co., Ltd. (“MicroPort® EP”) has recently received approval from China’s National Medical Products Administration (NMPA) for its Disposable Intracardiac Mapping Catheter.

Atrial fibrillation is the most common type of persistent cardiac arrhythmia. Cardiac electrophysiological examination is required for the diagnosis and treatment of patients with atrial fibrillation. It involves recording an intracardiac ECG by feeding an electrode catheter into a specific intracardiac area to identify any issue with the cardiac conduction system. The Disposable Intracardiac Mapping Catheter is designed for use in EP examinations and for mapping patients’ pulmonary vein signals during cryoablation procedures to assist in doctors’ diagnosis and treatment.

The approval of this product further diversifies and improves the portfolio of MicroPort® EP’s diagnostic catheters and cryoablation catheters, laying a solid foundation for its entry into the cryoablation segment. In the future, MicroPort® EP will continue to develop a total solution platform integrating active and passive solutions as well as devices and equipment, providing better products and services for patients and doctors.
Four Firehawk™ and Firefighter™ Products Receive Registration Approval in Saudi Arabia

Shanghai MicroPort Medical (Group) Co. Ltd. (MicroPort®) recently received registration approval from the Saudi Food and Drug Authority for four of its proprietary products. These include Firehawk™ Rapamycin Target Eluting Coronary Stent System (Firehawk™), Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System (Firehawk Liberty™), Firefighter™ PTCA Balloon Catheter (Firefighter™), and Firefighter™ NC PTCA Balloon Catheter (Firefighter™ NC).

It is expected that the marketing approval in Saudi Arabia will further expand the company’s global presence, while MicroPort® continues to grow within the local market to provide quality and integrated solutions for patients and doctors across the country.
MicroPort® EP Obtains Approval for its Medical Consumables and Equipment in Egypt

Shanghai MicroPort EP MedTech Co., Ltd. (“MicroPort® EP”) has recently obtained registration approval by the Egyptian Drug Authority (EDA) for its proprietary catheters, sheaths and other equipment, marking its first entry into the Egyptian market.

The catheters and equipment approved for use in Egypt are intended for the quick diagnosis and effective treatment of arrhythmias. Those approved include FireMagic™ Cardiac RF Ablation Catheter, FireMagic™ 3D Irrigated Ablation Catheter, EasyFinder™ Fixed Curve Diagnostic Catheter, EasyFinder™ Steerable Curve Diagnostic Catheter, EasyLoop™ Circular Mapping Catheter, PathBuilder™ Transseptal Guiding Introducer, Columbus™ 3D EP Navigation System, Columbus™ Cardiac Electrophysiology Stimulator, OptimAblate™ Cardiac RF Generator and OptimAblate™ Irrigation Pump.

The approval of these products in Egypt marks the official entry of MicroPort® EP in the Egyptian market and its further expansion in Africa, providing local patients and doctors with a comprehensive integrated medical solution for cardiac electrophysiology.
Horizon Medical™’s Daylily™ Embryo Transfer Catheter Receives Registration Approval in Thailand

The Daylily™ Embryo Transfer Catheter developed by Shanghai Horizon Medical™ Co., Ltd. (Horizon Medical™) has recently received registration approval from Thailand Food and Drug Administration (TFDA). It is the company’s second registered product in Thailand, following the approval of the LOTUS™ Ovum Aspiration Needle.

The Daylily™ embryo transfer catheter is used in embryo transfer procedures, allowing doctors to gently implant the in vitro embryos in the mother’s uterine cavity via her cervix within a short period of time. Available in a variety of sizes, the Daylily™ embryo transfer catheter provides doctors with a wide selection to fit their usage habits and patients’ different conditions.

The Daylily™ embryo transfer catheter was registered and approved in China in 2020, and has received recognition by experts in clinical applications. In the future, Horizon Medical™ will further improve its product portfolio and accelerate its market expansion at home and abroad.
First Patient Enrolled in MicroPort's TARGET IV NA Clinical Trial for the Firehawk™ Stent System to Obtain Regulatory Approval in the United States, Canada and Japan

On February 19, 2021, Shanghai MicroPort Medical (Group) Co. Ltd. (MicroPort®) announced that the first patient was enrolled in the TARGET IV NA, the clinical trial designed to assess the safety and effectiveness of the Firehawk™ Target Eluting Stent system in support of U.S. Food and Drug Administration (FDA), Canada and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions. The TARGET IV NA clinical program is anticipated to enroll approximately 1,616 patients at up to 100 sites in the United States, Canada, Europe, and Japan.

"The launch of the TARGET IV NA clinical trial is a tremendous milestone for MicroPort®," said Dr. Ming Zheng, the First president of Clinical Science and Medical affairs at MicroPort®. "We look forward to continuing to expand on the body of medical evidence that is already available to support the use of Firehawk to increase the advanced treatment options available to physicians and patients in the US, Canada and Japan."
MicroPort Orthopedics Announces Launch of HA Coated Collared Hip Stem and Cemented Collared Hip Stem, Expanding its Hip Stem Portfolio

MicroPort Orthopedics, a subsidiary of MicroPort Scientific Corporation (Stock code: 00853.HK), an international leader in orthopedic devices and technologies, announced the availability of its Profemur™ Gladiator™ HA Collared Stem and Profemur™ Gladiator™ Cemented Collared Stem.

Combined with its current Profemur™ Gladiator™ Plasma Stem, the Gladiator™ Hip Stem System is now complete, offering a wide range of indications in the treatment of both high demand total hip arthroplasties and low demand fracture patients.

“By allowing surgeons to cater a femoral hip system to their preferred techniques, we have created a customizable hip system that is Simply Versatile™ in its ability to exceed the needs of each surgeon, designed to help our surgeons more effectively treat patients” said Benny Hagag, President of MicroPort Orthopedics.
MicroPort® Subsidiary MicroPort CardioFlow Goes Public on SEHK

On February 4, 2021, MicroPort CardioFlow Medtech Corporation (“MicroPort CardioFlow”, stock code: 2160), a subsidiary of MicroPort Scientific Corporation (“MicroPort”, stock code: 00853) was successfully listed on the Main Board of the Stock Exchange of Hong Kong Limited (SEHK), which is the second listed subsidiary of MicroPort after the listing of Endovastec™ on the SSE STAR Market.

Founded in 2015, MicroPort CardioFlow specializes in providing total medical solutions for the treatment of the most common aortic and mitral valve diseases, including aortic stenosis and mitral regurgitation. Approved by China’s National Medical Products Administration (NMPA) in July 2019, VitaFlow™ is the first-generation transcatheter aortic valve product self-developed by MicroPort CardioFlow. This product is the first product that uses bovine pericardium as valve tissue in China, innovatively features the first-in-China double-layer polyethylene terephthalate skirt and the only marketed motorized delivery system worldwide; its stent outflow tract is designed with big cells to allow space for possible subsequent coronary interventions in patients. These unique designs, combined with in-house developed Alwide™ balloon catheter and Alpass™ catheter sheath, have enabled MicroPort CardioFlow the only medical device company in China that has a comprehensive offering of in-house developed complementary TAVI procedural accessories. Currently, MicroPort CardioFlow has submitted the registration application to the NMPA for its in-house developed second-generation TAVI product, VitaFlow™ II. The company is also carrying out clinical trials in Europe in order to obtain the EU CE Mark in near future.

“The listing of MicroPort CardioFlow on SEHK is another important milestone in the development of MicroPort and it brings a broader scope of opportunities for our future development.” announced Dr. Luo Qiyi, Chief Technology Officer of MicroPort, and Non-Executive Director and Chairman of MicroPort CardioFlow.
MicroPort® CRM Partners with the Start-up Bepatient to Conduct a Clinical Research Program on Heart Failure Patients

MicroPort® CRM, a pioneer in the field of Cardiac Rhythm Management (CRM) has announced its partnership with the French start-up bepatient™ to launch a clinical study on heart failure (HF) patients using remote monitoring.

This observational e-cohort study, to be conducted in France and sponsored by bepatient™, is designed to better describe how heart failure care is delivered in real life, and to collect data that will help inform the development of new devices and applications to improve patient outcomes.

“Collecting real world patient data is key to our clinical research and the use of connected medical devices opens up new possibilities,” said Amel Amblard, Vice President of Clinical Affairs at MicroPort® CRM. "The partnership with bepatient™ gives us the opportunity to enrich the data collected through our implanted devices and to make a leap forward in the care of patients with the ultimate objective of predicting cardiac decompensation events.”
MicroPort® CRM Launches MicroPort Academy CRM, an Education Website Dedicated to Healthcare Professionals

MicroPort CRM, a subsidiary of MicroPort Scientific Corporation (Stock code: 00853.HK), a pioneering company in the field of Cardiac Rhythm Management, has launched an online education website, MicroPort Academy CRM. The website is dedicated to Healthcare Professionals who want to enhance their knowledge about cardiac pacing therapy and the functionality of MicroPort CRM products. It was developed in collaboration with Stimuprat Editions, and designed by world-renowned experts in cardiac pacing.

MicroPort Academy CRM provides personalized and interactive training plans, ranging from diagnosis of ECG tracings to techniques of pacemaker implantation, programming simulation and troubleshooting. The site is open to health care professionals worldwide, and is aimed at both beginners and experienced people in cardiac rhythm management.

“Providing additional training to healthcare professionals to support them in better understanding and use of our products has always been part of our mission”, said Benoit Clinchamps, President of MicroPort CRM. “Our goal is to provide the highest quality training and ensure it is accessible to everyone, all over the world. To launch this website as part of our mission, we relied on electrophysiologists who are not only experts, but who are also guided by their passion to share their experience and knowledge.”
Investor Newsletter

Issue 02 2021

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com